[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631068":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":10,"locations":11,"responsibleParty":31,"collaborators":10,"id":33,"slug":10,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":10,"eligibilityCriteria":38,"healthyVolunteers":39,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":49,"overallStatus":14,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Glyance","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Subjects over 18 years old, willing to undergo non-surgical aesthetic procedures with AnGelHA 2",null,[12],{"facility":13,"status":14,"city":15,"state":16,"zip":17,"country":16,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":25},"Glyance Ltd","RECRUITING","Lod","Israel","7152026","IL",{"type":20,"coordinates":21},"Point",[22,23],34.8903,31.9467,{"lat":23,"lon":22},[26],{"name":27,"role":28,"phone":29,"phoneExt":10,"email":30},"Rachel Shemesh","CONTACT","+972535514894","rachel@axecium.com",{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100631068",false,"NCT07495865","Post-market Clinical Follow-up (PMCF) Study of Safety and Performance of 502-01 AnGelHA 2","A Prospective, Open-label, Non-interventional Post-market Study Evaluating the Performance and Safety of AnGelHA 2 Filler for Correcting Moderate to Severe Wrinkles and Folds and Facial Contour Remodeling in Routine Clinical Use.","Inclusion Criteria:\n\n* Men or women of any race, 18 years of age or older.\n* Able to read, understand and sign informed consent.\n\nExclusion Criteria:\n\n* Pregnant or lactating women (contraindications as per IFU).\n* Having received prior dermal filler injections in the six months preceding the study.\n* Previously treated with semi-permanent or permanent filler in the intended injection area.\n* Presenting with a cutaneous disorder, inflammation or infection near to the treatment area.\n* Known hypersensitivity to lidocaine and\u002For lidocaine HCl or hyaluronic acid.\n* Metabolic or endocrine uncontrolled disease, anaphylaxis, severe allergies or uncontrolled immune disorder.\n* Undergoing or planning to undergo peeling treatment or laser-\u002Fultrasound-based treatment within 3 weeks before or after injection.\n* Have received anti-coagulation, anti-platelet, or thrombolytic medications (e.g., warfarin), anti- inflammatory drugs (NSAIDs such as aspirin, ibuprofen), or other substances known to prolong time of coagulation from a week before treatment. A wash-out period of a week is allowed.\n* Subject, who has a condition or is in Fuse",true,"ALL","18 Years",{"count":43,"type":44},87,"ESTIMATED","OBSERVATIONAL","Post-market clinical follow-up (PMCF) investigation to evaluate the performance and safety of AnGelHA 2 filler for the correction of moderate to severe wrinkles and folds and facial contour remodeling, in a routine clinical setting.",[48],"Wrinkles",[48],"2026-05-26",{"date":52,"type":53},"2026-05-28","ACTUAL",{"date":55,"type":53},"2026-02-08",{"date":57,"type":44},"2027-03-12",{"name":5,"class":6},1]